Evidence map›Paper›PMID 32979667›Full record

ReviewAmerican journal of otolaryngology

Considerations for povidone-iodine antisepsis in pediatric nasal and pharyngeal surgery during the COVID-19 pandemic.

Stephen R Chorney, Mark D Rizzi, Kavita Dedhia

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of otolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Diagnostic and surgical innovations in otolaryngology for adult and paediatric patients during the COVID-19 era.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2022
    Review
  8. Article
  9. Adenotonsillectomy in high risk patients: Hematologic abnormalities and COVID-19 considerations.World journal of otorhinolaryngology - head and neck surgery · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Stephen R ChorneyDepartment of Otolaryngology-Head & Neck Surgery, University of Texas Southwestern Medical Center, Dallas, TX, 75207, USA; Children's Medical Center Dallas, Dallas, TX, 75235, USA. Electronic address: stephen.chorney@utsouthwestern.edu.
Mark D RizziDivision of Otolaryngology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Otorhinolaryngology - Head and Neck Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: rizzim@email.chop.edu.
Kavita DedhiaDivision of Otolaryngology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Otorhinolaryngology - Head and Neck Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: dedhiak@email.chop.edu.
University of Pennsylvania · USThe University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSurgeons resuming elective procedures during the COVID-19 pandemic should consider strategies to mitigate risk of exposure. For otolaryngologists performing surgery on children, unique vulnerability to SARS-CoV-2 results from a regular interface with the upper respiratory tract mucosa. A growing interest in perioperative application of povidone‑iodine (PVP-I) to the nasopharynx and oropharynx has emerged. The purpose of this review is to provide an evidence-based assessment of PVP-I in pediatric oral, nasal and pharyngeal surgery.

methodsA contemporary literature review with algorithmic approach to the potential use of PVP-I in pediatric mucosal surgery.

resultsSeveral formulations of PVP-I have shown rapid in vitro virucidal activity against SARS-CoV-2. Antisepsis using 1.0% PVP-I mouthwash and 0.45% PVP-I throat spray can occur after 30 seconds of contact time. To date, in vivo effectiveness of PVP-I against SARS-CoV-2 has yet to be established and possible risks of its direct use on upper aerodigestive mucosa of children must be weighed.

conclusionFurther research is required prior to strongly recommending PVP-I use in preparation for nasal, oral or pharyngeal surgery in children.

Indexed as

Otorhinolaryngologic Surgical ProceduresAnti-Infective Agents, LocalBetacoronavirusChildCoronavirus InfectionsCOVID-19HumansInfectious Disease Transmission, Patient-to-ProfessionalNasopharynxOropharynxPandemicsPneumonia, ViralPovidone-IodineSARS-CoV-2Anti-Infective Agents, LocalPovidone-IodineAntisepticCOVID-19Pediatric otolaryngologyPovidone-iodineSurgeryTonsillectomy

Identifiers

PMID32979667
PMCPMC7501061
OpenAlexW3087120693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.